ClinicalTrials.gg
CompletedNCT02482129Updated Jul 2, 2018Results posted

Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis

A Phase 2 interventional study of LME636 60 mg/mL ophthalmic solution and Dexamethasone 0.1% ophthalmic solution in Acute Anterior Uveitis, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-02.

Sponsored by Alcon Research (part of Alcon) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to determine whether topical ocular administration of LME636 60 mg/mL is efficacious in resolving the ocular inflammation in the anterior chamber (AC) associated with acute anterior uveitis (AAU).

Read the detailed description

Eligible subjects will be randomized to LME636 or Dexamethasone in a 3:1 ratio at the time they present to the trial site with the AAU flare and will enter treatment for 28 full days. Subjects with worsening disease from Visit 2/Day 4 onward or subjects without improvement after 14 days of treatment will be discontinued from treatment, unmasked and treated with a rescue regimen at the discretion of the investigator.

02

Conditions studied

  • Acute Anterior Uveitis

Browse trials for

Keywords

  • Acute anterior uveitis
  • LME636
03

In context

Uveitis, Anterior

56 studies on the registry are indexed under Uveitis, Anterior; 9 are open to participants now.

This study's enrollment of 45 is close to the median of 50 across 45 interventional studies indexed under Uveitis, Anterior.

Browse Uveitis, Anterior studies →

Lead sponsor

Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.

Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written .
  • Diagnosis of non-infectious AAU in at least 1 eye.
  • Anterior chamber cell score of 2+ or 3+ as per Standardization of Uveitis Nomenclature (SUN) in at least one eye.
  • Able to communicate well with the Investigator, to understand and comply with the requirements of the study.
  • Other protocol-specified inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Women of unwilling to use effective methods as defined in the protocol.
  • AC cell score of 4+ (SUN) or hypopyon.
  • Onset of anterior uveitis more than 2 weeks prior to enrollment in the study.
  • Presence of intermediate-, posterior-, or panuveitis in either eye.
  • Administration of stable doses >10 mg daily systemic prednisone or as described in the protocol.
  • Recurrent corneal abrasion or ulceration in either eye (past or present).
  • Tuberculosis (past or present).
  • Other protocol-specified exclusion criteria may apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    LME636

    LME636 60 mg/mL ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 1 week (Week 3) and 1 week of masked Vehicle administration (Week 4)

    Drug: LME636 60 mg/mL ophthalmic solution · Drug: LME636 Vehicle

  • Active comparator
    Dexamethasone

    Dexamethasone 0.1% ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 2 weeks (Weeks 3 and 4)

    Drug: Dexamethasone 0.1% ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Responders at Day 15

    Response was defined as a two-step decrease or more from baseline in Anterior Chamber (AC) Cell Grade as per Standardization of Uveitis Nomenclature (SUN). Baseline was defined as the measurement taken before drug administration on Day 1. Subjects receiving rescue treatment on or before Day 15 were considered non-responders. Only one eye contributed to the analysis.

    Time frame: Baseline (Day 1), Day 15

  2. Mean Best Corrected Visual Acuity (BCVA) at Each Visit

    Visual Acuity (VA) with the subject's best spectacles or other visual corrective devices was measured using an Early Treatment of Diabetic Retinopathy Study (ETDRS) or Snellen visual acuity chart and reported in letters read correctly. An increase (gain) in letters read indicates improvement. Only one eye contributed to the analysis.

    Time frame: Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29

  3. Mean Intraocular Pressure (IOP) at Each Visit

    IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry or Tonopen and reported in millimeters mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Only one eye contributed to the analysis.

    Time frame: Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29

  4. Number of Subjects With Increase From Baseline in Slit Lamp Parameters at Any Post-Treatment Visit

    Slit-lamp biomicroscopy (examination) was performed to evaluate the anterior segment of the eye, including lids/lashes, conjunctiva, cornea, anterior chamber (cells and flare), iris, and lens. Ocular signs were categorized as Aqueous Flare, Aqueous Inflammatory Cell Grade, Keratic Precipitates, Lens, Limbal Injection, Status of Lens, Peripheral Anterior Synechia, and Posterior Synechia. An increase indicates worsening. Only one eye contributed to the analysis.

    Time frame: Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29

  5. Number of Subjects With an Increase From Baseline in Dilated Fundus Parameters at Any Post-Treatment Visit

    The dilated fundus examination was performed to evaluate the health of the vitreous, optic disc, retinal vessels, macula, and retinal periphery. An increase indicates worsening. Only one eye contributed to the analysis.

    Time frame: Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29

Secondary outcomes

  1. Number of Subjects With IOP Change From Baseline to Last On-Treatment Assessment

    IOP was assessed using Goldmann applanation tonometry or Tonopen and reported in mmHg. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Only one eye contributed to the analysis.

    Time frame: Baseline (Day 1), Up to Day 29

  2. Mean Change From Baseline in BCVA at Each Visit

    Visual Acuity (VA) was measured with the participant's best spectacles or other visual corrective device in place using an ETDRS or Snellen visual acuity chart. Improvement of BCVA was defined as an increase (gain) in letters read from the baseline assessment. Only one eye contributed to the analysis.

    Time frame: Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29

  3. Time-to-Response

    Time-to-Response was defined as the number of days from baseline to the first scheduled visit when a two-step decrease or more from baseline in AC Cell Grade (as per SUN) was observed. Time-to-Response is reported as number of subjects presenting time-to-response by visit. Only one eye contributed to the analysis.

    Time frame: Baseline (Day 1), Up to Day 15

  4. Use of Rescue Treatment

    Use of rescue treatment is presented as the number of subjects with first use of rescue treatment by visit. Subjects receiving rescue medication were not considered withdrawn and the collection of data continued after discontinuation of study treatment. Only one eye contributed to the analysis.

    Time frame: Day 4, Day 8, Day 15

  5. Mean Serum Concentration of Total LME636 at Each Visit

    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. Concentrations below the limit of quantification (BLQ), defined as 0.25 ng/mL, were reported as NA with no imputation for missing data.

    Time frame: Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29

  6. Number of Subjects With Anti-LME636 Antibodies Present at Each Visit

    Serum samples were collected and assessed for anti-LME636 antibodies. Samples collected from subjects in the LME636 dose group were analyzed for anti-LME636 antibodies. For subjects in the dexamethasone group, only the samples collected on Day 1 (ie, prior to the start of treatment) were analyzed for anti-LME636 antibodies.

    Time frame: Day 1, Day 4, Day 8, Day 15, Day 22, Day 29

07

Results

Posted Aug 28, 2017

Participant flow

Subjects were recruited from 10 study centers located in the United States.

Participant flow — Overall Study
MilestoneLME636Dexamethasone
Started3211
Treated, as randomized309
Completed269
Not completed62
Withdrew: Adverse event-prior to treatment01
Withdrew: Withdrawal by subject-prior to treatment01
Withdrew: Unable to draw blood-prior to treatment10
Withdrew: Criteria not met-prior to treatment10
Withdrew: Adverse event10
Withdrew: Withdrawal by subject20
Withdrew: Criteria not met10

Outcome measures

PrimaryNumber of Responders at Day 15

Response was defined as a two-step decrease or more from baseline in Anterior Chamber (AC) Cell Grade as per Standardization of Uveitis Nomenclature (SUN). Baseline was defined as the measurement taken before drug administration on Day 1. Subjects receiving rescue treatment on or before Day 15 were considered non-responders. Only one eye contributed to the analysis.

Time frame:
Baseline (Day 1), Day 15
Reported as:
Count of participants · Participants
Number of Responders at Day 15
ParticipantsLME636Dexamethasone
Number of Responders at Day 15149
PrimaryMean Best Corrected Visual Acuity (BCVA) at Each Visit

Visual Acuity (VA) with the subject's best spectacles or other visual corrective devices was measured using an Early Treatment of Diabetic Retinopathy Study (ETDRS) or Snellen visual acuity chart and reported in letters read correctly. An increase (gain) in letters read indicates improvement. Only one eye contributed to the analysis.

Time frame:
Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29
Reported as:
Mean · letters
Mean Best Corrected Visual Acuity (BCVA) at Each Visit
lettersLME636Dexamethasone
Baseline71.1 ± 14.5877.2 ± 14.69
Day 470.5 ± 13.9277.9 ± 12.94
Day 872.1 ± 13.6276.8 ± 11.50
Day 1574.1 ± 10.1177.1 ± 11.82
Day 2274.5 ± 10.4178.2 ± 11.31
Day 2973.8 ± 11.7079.2 ± 11.23
PrimaryMean Intraocular Pressure (IOP) at Each Visit

IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry or Tonopen and reported in millimeters mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Only one eye contributed to the analysis.

Time frame:
Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29
Reported as:
Mean · mmHg
Mean Intraocular Pressure (IOP) at Each Visit
mmHgLME636Dexamethasone
Baseline (Day 1)15.2 ± 5.0915.5 ± 4.12
Day 414.8 ± 3.7415.3 ± 3.47
Day 814.1 ± 3.4016.1 ± 3.51
Day 1514.0 ± 3.3816.0 ± 5.06
Day 2214.6 ± 3.1417.0 ± 4.57
Day 2915.5 ± 4.7216.3 ± 4.40
PrimaryNumber of Subjects With Increase From Baseline in Slit Lamp Parameters at Any Post-Treatment Visit

Slit-lamp biomicroscopy (examination) was performed to evaluate the anterior segment of the eye, including lids/lashes, conjunctiva, cornea, anterior chamber (cells and flare), iris, and lens. Ocular signs were categorized as Aqueous Flare, Aqueous Inflammatory Cell Grade, Keratic Precipitates, Lens, Limbal Injection, Status of Lens, Peripheral Anterior Synechia, and Posterior Synechia. An increase indicates worsening. Only one eye contributed to the analysis.

Time frame:
Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29
Reported as:
Number · participants
Number of Subjects With Increase From Baseline in Slit Lamp Parameters at Any Post-Treatment Visit
participantsLME636Dexamethasone
Aqueous Flare91
Aqueous Inflammatory Cell Grade41
Keratic Precipitates40
Lens00
Limbal Injection70
Status of Lens00
Peripheral Anterior Synechia11
Posterior Synechiae81
PrimaryNumber of Subjects With an Increase From Baseline in Dilated Fundus Parameters at Any Post-Treatment Visit

The dilated fundus examination was performed to evaluate the health of the vitreous, optic disc, retinal vessels, macula, and retinal periphery. An increase indicates worsening. Only one eye contributed to the analysis.

Time frame:
Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29
Reported as:
Number · participants
Number of Subjects With an Increase From Baseline in Dilated Fundus Parameters at Any Post-Treatment Visit
participantsLME636Dexamethasone
Macula20
Optic Nerve10
Retina10
Vitreous40
SecondaryNumber of Subjects With IOP Change From Baseline to Last On-Treatment Assessment

IOP was assessed using Goldmann applanation tonometry or Tonopen and reported in mmHg. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Only one eye contributed to the analysis.

Time frame:
Baseline (Day 1), Up to Day 29
Reported as:
Count of participants · Participants
Number of Subjects With IOP Change From Baseline to Last On-Treatment Assessment
ParticipantsLME636Dexamethasone
Increase > 30 mmHg00
Increase 11-30 mmHg10
Increase 6-10 mmHg02
-5 mmHg Decrease - 5 mmHg Increase258
Decrease 6-10 mmHg10
Decrease 11-30 mmHg20
Decrease > 30 mmHg00
SecondaryMean Change From Baseline in BCVA at Each Visit

Visual Acuity (VA) was measured with the participant's best spectacles or other visual corrective device in place using an ETDRS or Snellen visual acuity chart. Improvement of BCVA was defined as an increase (gain) in letters read from the baseline assessment. Only one eye contributed to the analysis.

Time frame:
Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29
Reported as:
Mean · letters
Mean Change From Baseline in BCVA at Each Visit
lettersLME636Dexamethasone
Baseline (BL)71.1 ± 14.5877.2 ± 14.69
Change from BL at Day 4-0.1 ± 9.740.7 ± 5.40
Change from BL at Day 80.0 ± 12.84-0.4 ± 6.19
Change from BL at Day 152.1 ± 9.53-0.1 ± 3.73
Change from BL at Day 222.8 ± 9.101.0 ± 5.06
Change from BL at Day 292.1 ± 10.362.0 ± 5.37
SecondaryTime-to-Response

Time-to-Response was defined as the number of days from baseline to the first scheduled visit when a two-step decrease or more from baseline in AC Cell Grade (as per SUN) was observed. Time-to-Response is reported as number of subjects presenting time-to-response by visit. Only one eye contributed to the analysis.

Time frame:
Baseline (Day 1), Up to Day 15
Reported as:
Count of participants · Participants
Time-to-Response
ParticipantsLME636Dexamethasone
Day 497
Day 852
Day 1510
Non-Responder101
SecondaryUse of Rescue Treatment

Use of rescue treatment is presented as the number of subjects with first use of rescue treatment by visit. Subjects receiving rescue medication were not considered withdrawn and the collection of data continued after discontinuation of study treatment. Only one eye contributed to the analysis.

Time frame:
Day 4, Day 8, Day 15
Reported as:
Count of participants · Participants
Use of Rescue Treatment
ParticipantsLME636Dexamethasone
Day 430
Day 830
Day 1500
No Rescue1910
SecondaryMean Serum Concentration of Total LME636 at Each Visit

Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. Concentrations below the limit of quantification (BLQ), defined as 0.25 ng/mL, were reported as NA with no imputation for missing data.

Time frame:
Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29
Reported as:
Mean · ng/mL
Mean Serum Concentration of Total LME636 at Each Visit
ng/mLLME636
Day 1NA ± NA
Day 4NA ± NA
Day 8NA ± NA
Day 15NA ± NA
Day 220.2510 ± 0.31237
Day 29NA ± NA
SecondaryNumber of Subjects With Anti-LME636 Antibodies Present at Each Visit

Serum samples were collected and assessed for anti-LME636 antibodies. Samples collected from subjects in the LME636 dose group were analyzed for anti-LME636 antibodies. For subjects in the dexamethasone group, only the samples collected on Day 1 (ie, prior to the start of treatment) were analyzed for anti-LME636 antibodies.

Time frame:
Day 1, Day 4, Day 8, Day 15, Day 22, Day 29
Reported as:
Count of participants · Participants
Number of Subjects With Anti-LME636 Antibodies Present at Each Visit
ParticipantsLME636Dexamethasone
Day 153
Day 45—
Day 86—
Day 1511—
Day 2217—
Day 2918—

Adverse events

Collected over Adverse events (AEs) were collected from time of consent for the duration of a subject's participation in the study (up to 35 days). AEs are reported as pretreatment, treatment-emergent, and posttreatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pretreatment0/45 (0%)0/45 (0%)0/45 (0%)
LME6360/29 (0%)1/29 (3.4%)13/29 (44.8%)
Dexamethasone0/10 (0%)0/10 (0%)6/10 (60%)
Posttreatment0/39 (0%)0/39 (0%)0/39 (0%)
Most frequent serious events
Most frequent serious events
EventPretreatmentLME636DexamethasonePosttreatment
Multiple sclerosisNervous system disorders0/451/290/100/39
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPretreatmentLME636DexamethasonePosttreatment
Anterior chamber cellEye disorders0/454/291/100/39
Eye painEye disorders0/454/290/100/39
Anterior chamber flareEye disorders0/453/290/100/39
IridocyclitisEye disorders0/453/291/100/39
Iris adhesionsEye disorders0/453/290/100/39
PhotophobiaEye disorders0/453/290/100/39
Ciliary muscle spasmEye disorders0/450/291/100/39
IritisEye disorders0/450/291/100/39
Lacrimation increasedEye disorders0/450/291/100/39
Vitreous detachmentEye disorders0/450/291/100/39

Baseline characteristics

This analysis population includes all randomized and treated subjects, as treated.

Age, Continuous
Age, Continuous(years)LME636DexamethasoneTotal
Mean54.1 ± 17.2055.6 ± 16.0254.5 ± 16.71
Sex: Female, Male
Sex: Female, Male(Participants)LME636DexamethasoneTotal
Female17421
Male12618
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2015 to primary completion in Mar 2016, 8 months.

Results were first posted in Aug 2017, 1 year 5 months after primary completion. A results delay was requested in Jan 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2015
First posted
Jun 26, 2015
StartActual
Jul 17, 2015
Primary completionActual
Mar 21, 2016
CompletionActual
Mar 21, 2016
Results delay requested
Jan 13, 2017
Results first posted
Aug 28, 2017
Last update
Jul 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02482129
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Jun 26, 2015
Start date
Jul 17, 2015
Primary completion
Mar 21, 2016
Completion
Mar 21, 2016
Results posted
Aug 28, 2017
Last update
Jul 2, 2018

Study contacts

Clinical Scientist NIBR, Alcon
study director · Alcon Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Licaminlimab

Start the discussion